.JPG?ad=18503&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Gynecology and Obstetrics [R. H., T. B.], Pathology [E. W.], and Internal Medicine [K. O.], University Hospital, S-751 85, Uppsala; Ludwig Institute for Cancer Research, Biomedical Center, Box 595, S-751 24 Uppsala [K. F.]; and Department of Gynecologic Oncology, University Hospital, S-751 85 Uppsala [M. R.], Sweden
2 To whom requests for reprints should be addressed.
The expression of platelet-derived growth factor (PDGF), PDGF-
receptor (PDGFR) and PDGF-β receptor (PDGFRβ) was studied in normal ovaries and ovarian neoplasms by immunohistochemical analysis. PDGF was detected in tumor cells in 33 of 45 malignant tumor samples but in none of 20 benign tumors (P < 0.001) or 11 normal ovaries (P < 0.001). In borderline tumors, 4 of 7 tissues stained positive in tumor cells. PDGFR was detected in tumor cells in 16 of 45 malignant tumors, while no epithelial staining was found in 16 benign tumors (P = 0.002) or in 10 normal ovaries (P = 0.023). In 1 of 7 borderline neoplasms, tumor cells expressed PDGFR. Neither normal epithelium nor tumor cells stained positive with antibodies against PDGFRβ.
Patients with ovarian cancer and PDGFR-positive tumor cells demonstrated an overall shorter survival compared to those who had negatively stained tumors (P < 0.005). A similar correlation was found in patients having stage III ovarian cancer (P < 0.01), which further supports an independent role for PDGFR as a prognostic factor.
Thus, the concomitant expression of PDGF and PDGFR in tumor cells is related to progression of malignant ovarian tumors, indicating a functional role of PDGF via autocrine growth stimulation.
1 This work was supported by Lions Cancer Foundation; Erik, Karin and Gosta Selanders Foundation; Swedish Cancer Research Foundation (RMC, Project No. 1925-B91-06XAC, 1759).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 3/22/93. Accepted 7/27/93.
This article has been cited by other articles:
|
|
 |
|
  R. P. Rocconi, K. S. Matthews, K. J. Kimball, M. G. Conner, A. C. Baker, and M. N. Barnes Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors Reproductive Sciences, September 1, 2008; 15(7): 673 - 677. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. N. Fehrmann, X.-y. Li, A. G. J. van der Zee, S. de Jong, G. J. te Meerman, E. G. E. de Vries, and A. P. G. Crijns Profiling Studies in Ovarian Cancer: A Review Oncologist, August 1, 2007; 12(8): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Matei, M. Satpathy, L. Cao, Y.-C. Lai, H. Nakshatri, and D. B. Donner The Platelet-derived Growth Factor Receptor {alpha} Is Destabilized by Geldanamycins in Cancer Cells J. Biol. Chem., January 5, 2007; 282(1): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Chen, J. Aravindakshan, Y. Yang, R. Tiwari-Pandey, and M.R. Sairam Aberrant expression of PDGF ligands and receptors in the tumor prone ovary of follitropin receptor knockout (FORKO) mouse Carcinogenesis, May 1, 2006; 27(5): 903 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Kumar, J. H. Ha, R. Radhakrishnan, and D. N. Dhanasekaran Transactivation of Platelet-Derived Growth Factor Receptor {alpha} by the GTPase-Deficient Activated Mutant of G{alpha}12 Mol. Cell. Biol., January 1, 2006; 26(1): 50 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Loizos, Y. Xu, J. Huber, M. Liu, D. Lu, B. Finnerty, R. Rolser, A. Malikzay, A. Persaud, E. Corcoran, et al. Targeting the platelet-derived growth factor receptor {alpha} with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target Mol. Cancer Ther., March 1, 2005; 4(3): 369 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Wang, Y. Ngalame, M. C. Panelli, H. Nguyen-Jackson, M. Deavers, P. Mueller, W. Hu, C. A. Savary, R. Kobayashi, R. S. Freedman, et al. Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer Clin. Cancer Res., January 1, 2005; 11(1): 113 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F Singer, G. Hudelist, W. Lamm, R. Mueller, K. Czerwenka, and E. Kubista Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors Endocr. Relat. Cancer, December 1, 2004; 11(4): 861 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Karlan Profiling the Perpetrator J. Clin. Oncol., December 1, 2004; 22(23): 4663 - 4664. [Full Text] [PDF]
|
|
|
|
|
|
D. Spentzos, D. A. Levine, M. F. Ramoni, M. Joseph, X. Gu, J. Boyd, Towia. A. Libermann, and S. A. Cannistra Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer J. Clin. Oncol., December 1, 2004; 22(23): 4700 - 4710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice Cancer Res., June 15, 2004; 64(12): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Apte, D. Fan, J. J. Killion, and I. J. Fidler Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma Clin. Cancer Res., February 1, 2004; 10(3): 897 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Huang, Y. Lin, Q. Shi, L. Flowers, S. Ramachandran, I. R. Horowitz, S. Parthasarathy, and R.-P. Huang Enhanced Protein Profiling Arrays with ELISA-Based Amplification for High-Throughput Molecular Changes of Tumor Patients' Plasma Clin. Cancer Res., January 15, 2004; 10(2): 598 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Matei, D. D. Chang, and M.-H. Jeng Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor {alpha} and Akt Inactivation Clin. Cancer Res., January 15, 2004; 10(2): 681 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al. The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically Clin. Cancer Res., August 1, 2003; 9(9): 3476 - 3485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Uehara, S. J. Kim, T. Karashima, D. L. Shepherd, D. Fan, R. Tsan, J. J. Killion, C. Logothetis, P. Mathew, and I. J. Fidler Effects of Blocking Platelet-Derived Growth Factor-Receptor Signaling in a Mouse Model of Experimental Prostate Cancer Bone Metastases J Natl Cancer Inst, March 19, 2003; 95(6): 458 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text]
|
|
|
|
 |
|
 C.-H. Heldin and B. Westermark Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor Physiol Rev, October 1, 1999; 79(4): 1283 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Duleba, R. Z. Spaczynski, A. Arici, R. Carbone, and H. R. Behrman Proliferation and Differentiation of Rat Theca-Interstitial Cells: Comparison of Effects Induced by Platelet-Derived Growth Factor and Insulin-Like Growth Factor-I Biol Reprod, March 1, 1999; 60(3): 546 - 550. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Mesiano, N. Ferrara, and R. B. Jaffe Role of Vascular Endothelial Growth Factor in Ovarian Cancer : Inhibition of Ascites Formation by Immunoneutralization Am. J. Pathol., October 1, 1998; 153(4): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Berchuck, A. Elbendary, L. Havrilesky, G. C. Rodriguez, and R. C. Bast Pathogenesis of Ovarian Cancers Reproductive Sciences, July 1, 1994; 1(3): 181 - 190. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
